Risk multipliers for severe food anaphylaxis by unknown
REVIEW Open Access
Risk multipliers for severe food anaphylaxis
Peter K Smith1*, Jonathan O’B Hourihane2 and Phil Lieberman3
Abstract
Anaphylaxis is a severe, life threatening allergic reaction. In most fatal cases of food anaphylaxis, the fatality is not due
merely to a simple, linear relationship between the allergen and exposure in a sensitized individual. Compounding
factors such as the allergic disease burden—particularly the presence of asthma; comprehension of the potential severity
of an event, training in the appropriate use of epinephrine, and emerging metabolic factors should be considered when
assessing risk and establishing management strategies. This paper reviews the factors that contribute to the risk of severe
anaphylactic events and provides a framework for the ongoing management of patients at risk of severe food allergy.
Review
Death from food anaphylaxis remains a rare but tragic
event [1]. The majority of fatal food anaphylaxis involves
children and young adults [1–3]. In most fatal cases
there is a combination of several known risk factors,
which often could have been individually mitigated. The
purpose of this review is to highlight known factors that
increase the risk for severe allergic reactions to food and
to present, in a practical and visual manner, strategies
that can be used to identify and deal with these factors
when taking a history, examining and planning manage-
ment for individuals with food allergy.
Anaphylaxis is a serious, life-threatening, generalized
hypersensitivity reaction that can occur via immunologic
(either IgE-dependent or IgE-independent) or non-
immunologic mechanisms [4]. Effective management of
potentially life-threating reactions involves review by an
allergist to identify causative allergens (and other aller-
gic risks to help reduce exposure), and the prescription
of and training in the use of epinephrine [5]. This refer-
ral for an evaluation should best occur at the emer-
gency care setting where, currently, under-diagnosis of
anaphylaxis is an issue [6]. The following aspects need
to be highlighted as particular risk factors for anaphyl-
axis, with an emphasis on food anaphylaxis.
Dose and type of allergen
With IgE dependent reactions it is considered axiomatic
that the dose of allergen that the sensitized individual is
exposed to determines the severity of the reaction [7, 8].
However it should be appreciated that a threshold dose
for symptoms can vary for an individual and between in-
dividuals. The concealment of allergen (hidden allergen)
can result in delayed recognition of an allergic food and
increase dose exposure. The median time from ingestion
of peanut to experiencing symptoms has been reported
to be as short as 3 minutes [9]. In adult subjects under-
going repeat peanut challenges, an increase in the lipid
matrix of a concealed peanut biscuit led to higher dosing
before the patient developed symptoms, and conse-
quently they experienced more severe allergic and ana-
phylactic reactions [10]. Other concealment/dosing
factors may include spicy foods where itch and burning
from spices could mimic allergic symptoms. Case series
have reported an apparent effect of alcohol/sedating
medication consumption, where symptom recognition is
reduced, though there are no published studies on dose-
thresholds related to these latter factors. The type of aller-
gen contributes to concealment and exposure risk. In a
threshold dose study, peanut caused more severe reactions
than other foods studied (hazelnut, egg and milk) [11]. In
a study investigating the correlation of dose with severity
of the reaction in a community setting and the threshold
dose of peanut in a double blind placebo controlled chal-
lenge, the amount of the dose did not relate significantly
to either the severity of the reaction or the dose of peanut
reportedly consumed in the community [12]. This sug-
gests that there are very important co-factors that influ-
ence the severity of food allergic reactions outside the
controlled clinical setting of a formal food challenge [13].
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Age
Youth—specifically teenage years and being a young
adult—is a risk factor for fatal reactions [1–3, 14, 15]. The
expected attributable social and emotional contributing
factors include risk-taking behavior with eating, disease
denial or treatment non-compliance (not carrying an
epinephrine auto-injector and poor asthma control) [16].
Although not specific to food allergy, Brown et al. re-
ported that older age was associated with more severe
hypoxemia with anaphylaxis episodes [17]. In a peanut
threshold dose study, adults with peanut allergy had more
severe reactions than children [11]. This finding has very
significant implications, for the majority of patients with
peanut allergy do not grow out of their sensitivity.
Late or absent treatment
Failure to use epinephrine, or to use it promptly is con-
sidered to be an important and avoidable factor in fatal
reactions [5, 17–21]. Combining the data of Bock and
Pumphrey in cases of fatal food anaphylaxis, only 5 of 80
patients had administered epinephrine appropriately [2,
3]. Intramuscular epinephrine in the community setting
is the standard of care for anaphylaxis, as inhaled
epinephrine devices are unreliable in children [22] and
subcutaneous epinephrine takes up to 30 minutes to
achieve significant serum levels [23, 24].
Asthma
Asthma is probably the most significant risk factor for
death from food allergy anaphylaxis, with case series
finding 69–100 % of patients having pre-existing asthma
[2, 3, 5, 13, 18–21, 25]. Summers and colleagues re-
ported that allergic burden contributes to the severity of
allergic reactions in patients with nut anaphylaxis [26]. In
patients with severe asthma the risk for life-threatening
bronchospasm during nut associated anaphylaxis was in-
creased 6.8 fold, although this relative risk was only 2.7
times for those patients with mild asthma. With active al-
lergic airway disease, an increase in mast cells, basophils,
neutrophils and eosinophils appear in the airways [27–30].
Cornell described a clinical entity of airway “priming” [31,
32], where pollen-allergic patients experience a greater al-
lergic reaction (and with smaller doses of allergens) at the
end of the pollen season than at the start. Priming has
been demonstrated experimentally [27, 28] and can be
reduced with the use of nasal steroids [33]. Priming
increases symptoms to both the priming antigen as well as
non-priming antigens and non-allergic stimuli [32]. We
hypothesize that the Summers et al. report, reflects in-
creased effector cell activity with allergic disease burden
due to “priming”, which resulted in more severe food al-
lergy reactions. Swedish children with inhalant allergies
suffer food anaphylaxis more commonly in their relevant
pollen season, compared to children without pollen
allergy, whose event rate is more stable through the year
[34]. Oral allergy syndrome (also called secondary food al-
lergy or pollen-food allergy) may increase in severity in
high pollen season [35]. Whilst oral allergy syndrome is
often regarded as mild disease, severe reactions including
anaphylaxis can occur [36].
Past history of severe allergic reactions
A history of severe allergic events including anaphylaxis
has been identified as a risk factor for fatal events due to
food and future severe allergic reactions [19, 37]. A his-
tory of anaphylaxis also appears to influence both the
dose of an allergen tolerated in patients receiving food
allergy oral immunotherapy and the risk of severe reac-
tions during oral food immunotherapy [38]. It should be
stressed that the about half of a UK series of food ana-
phylaxis deaths occurred in patients with a history of
mild reactions, thus there can be little reassurance based
on a history of previous mild reactions [39].
Allergic disease burden
In a case series of patients with nut allergy, severe rhin-
itis was associated with a 3.8 fold increased risk for se-
vere pharyngeal edema and severe eczema correlated
with a 3.1- fold increased risk of impaired consciousness
(presumably hypotension) with anaphylaxis events [26].
Although aging is physiological rather than a “disease”,
increasing age has been correlated with a higher risk of
severe cardiovascular symptoms [17, 40].
Physiological and medication
Multiple allergic mediators (e.g., tryptase, histamine,
platelet activating factor, IL-2, IL-6, IL-10 and soluble
tumor necrosis factor receptor I), have been correlated
with severity of anaphylactic reactions [17, 39-41]. These
mediators are products of the allergic reaction, rather
than being risk factors for anaphylaxis.
Variants in the catabolic capacity of two enzymes have
been correlated with risk for severity of anaphylaxis [17,
26]. Patients with serum angiotensin converting enzyme l
(ACE) levels in the lower quartile of normal (<37.0 mmol/
L) have been reported to have a 9.6 (1.6–57) - fold risk of
severe pharyngeal edema when experiencing anaphylaxis
from a nut source compared to those in the higher quar-
tile [26]. In a study of all forms of anaphylaxis, platelet ac-
tivating factor acetyl hydrolase activity (also known as
Lipoprotein-associated phospholipase A2) was found to
be associated with severe reactions in a proportion of pa-
tients [17]. Serum PAF levels have also been linked to ana-
phylaxis severity [42]. Platelet activating factor acetyl
hydrolase is responsible for PAF degradation in plasma
[43]. ACE is the main protease responsible for bradykinin
catabolism [44]. There are two allelic forms of ACE, and
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increased expression of the gene for the “I” allele has been
associated with more severe food allergy [45].
While medications cause most healthcare related epi-
sodes of anaphylaxis, only aspirin has been reported to
be related to food dependent exercise induced anaphyl-
axis [46, 47]. Beta-blockers, cox-inhibitors and ACE in-
hibitors have been reported as possible contributors to
the severity of all forms of anaphylaxis [13, 40], and both
Beta-blockers and ACE inhibitors have been associated
with mast cell priming [48]. Gliptins (which are used in
diabetes and inhibit a serine protease, have been re-
ported to augment ACE induced angioedema [49]. As-
pirin may cause increased gastrointestinal permeability,
and therefore the rapidity and amount of allergen levels
reaching the submucosa/systemic circulation. A 500 mg
dose of aspirin has been reported to increase the likeli-
hood of a positive food challenge in patients with wheat
dependent exercise induced anaphylaxis [47]. While not
specific for food, Brown et al. reported that use of car-
diovascular medications correlated with age but was not
associated with additional risk for reaction severity [17].
Menstruation may be another physiological state that
destabilizes the allergic status of an individual and the
relation of anaphylactic episodes to the menses should
be considered when appropriate.
Exercise
Exercise can cause anaphylaxis directly and is a co-factor
for food anaphylaxis, best defined as food dependent exer-
cise induced anaphylaxis (FDEIA). Wheat-derived omega 5
gliadin is the antigen most commonly recognized as caus-
ing this syndrome [50, 51]. A US series reported shellfish
crustaceans to be the allergen in 37 % of cases of FDIEA
[52]. Because of the multi-factorial nature of this condition,
the diagnosis can be difficult to make (the patient often ex-
periences multiple severe attacks over a prolonged time)
because the patient can tolerate the food remote from
exercise without symptoms. It is proposed that exercise in-
creases GI permeability and/or allergen digestion, so the
patient is exposed to greater levels of antigen [35, 53].
Exercise is a physiological state that increases release of
mediators (serotonin, bradykinin and endorphins), which
sensitize the calcium ion channel through which histamine
works, the transient receptor potential vanilloid 1 (TRPV1)
receptor [54]. This ion channel is present on both sensory
nerves and mast cells. Acidosis and rise in core body
temperature also directly agonize the TPRV1 ion channel
to further reduce the activation threshold to allergic prod-
ucts [54]. ATP, which increases with exercise, inhibits the
homeostatic de-activation of TRPV1 receptor [55].
Intercurrent illness
Infective illness has similar metabolic influences as exer-
cise, and there is evidence of immunological vulnerability
including mast cell activation [56]. The best data relating
to food allergy and a reduced threshold for food with in-
fective illness comes from food allergy oral immunother-
apy reports, where doses of tolerated allergen have a
higher rate of reaction during illness [57]. Hot showers
have also been reported to be associated with risk of reac-
tion to food allergens during immunotherapy [38]. Medi-
cations such as aspirin used to control symptoms and
fever with infections might also contribute to risk of se-
vere allergic reactions to food.
Comprehension and education
Anecdotal reports suggest there may be an effect of ethni-
city on the incidence of allergic reactions to foods though it
is unclear how this is mediated; it is possibly due to lan-
guage and cultural difficulties inhibiting equivalent access
to allergy focused clinical services and optimization of
asthma care.
Education provided regarding food allergy and anaphyl-
axis will enhance the prevention, recognition and appropri-
ate and timely therapy of anaphylactic reactions to food.
The authors are aware from coroners' reports that learning
difficulty (e.g., intellectual disability and language barriers)
have been found to be issues in food anaphylaxis deaths.
Other factors
Many allergists recognize ethanol as risk factor for food
allergy anaphylaxis, however, there is very little pub-
lished literature on this [58, 59]. Ethanol, like other rec-
reational drugs, can be associated with reduced
awareness, risk taking, and recognition of symptoms, as
well as interfering with an individual’s timely treatment
response to severe food allergy. Physiologically, ethanol
activates the TRPV1 channel, lowering the threshold to
activation by the multiple endogenous products of the
allergic response that act via this ion channel [54, 60].
Activation of the TRPV1 ion channel on sensory nerves
results in release of neuromediators including calcitonin
nerve related peptide to cause vasodilation [61]. The
vasodilation effect from ethanol could contribute to a
more severe shock in food allergy. Alcohol may also
cause gastritis, permitting greater allergen absorption.
Mastocytosis/mast cell tumors/mast cell activation
should be included in underlying risk factors for severity
of anaphylaxis in general, however, we are not aware of a
food allergy death being reported in a patient with docu-
mented mastocytosis/mast cell activation syndromes.
In summary
There are many layers to the risk of severe reactions in food
allergy. A model of augmenting factors has recently been
suggested [62]. We have developed 2 frameworks to con-
sider risk factors. These co-contributors are summarized in
Fig. 1. More severe and fatal reactions are likely to occur
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Fig. 1 Layers and multiplication factors relating to risk in severe food allergy: 1. Dose of antigen, which can be altered by concealment factors, 2.
Age—most deaths from food allergy are in the young, but older patients tend to have more severe reactions with nut allergy, 3. Timely effective
treatment, 4. Co-existent allergic burden, and 5. Metabolic/Pharmacologic factors including: capacity to catabolize allergic mediators, exercise,
illness, ethanol and medications.
Fig. 2 An allergic individual's response to an allergen may vary because of dose, treatment and threshold factors. Timely, effective treatment
limits, but does not control, all reactions. Apertures are larger depending on the presence of risk factors. Fatal and severe reactions appear more
likely if there is a combination and alignment of risk factors. In the example, a similar dose in patients with equivalent levels of severe food
allergy has different clinical outcomes. A mild reaction is the outcome in a patient with less current allergic disease, less metabolic factors, less
contributing medications and early effective use of epinephrine. These factors are shown to amplify in a severe allergic reaction
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with alignment of these layers-the so-called “swiss-cheese”
model, and a gap emerges. A larger aperture to “fall
through” opens with more risk factors, and the result is
likely to be a severe reaction if there is alignment (Fig. 2).
The role of the allergy specialist is critical in risk identifi-
cation, the communication of risk, treatment of co-
morbidities and having a supportive, empowering and
effective management plan in place with medications
on hand for patients and families to self treat when acci-
dentally exposed to food and other allergens.
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